Domperidone

BreastfeedingPediatric
  • TRADE NAMES: Evoxin; Motilium (Johnson & Johnson)
  • INDICATIONS: Investigational antiemetic, gastroesophageal reflux disease (GERD), nausea, vomiting
  • CLASS: Antiemetic, Dopamine receptor antagonist
  • HALF-LIFE: 7–8 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bromocriptine, Darifenacin, Hydromorphone, Ketoconazole, Meptazinol, Oxybutynin, Tiotropium, Trospium

PREGNANCY CATEGORY: N/A

Our database has 28 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of domperidone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/25/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top